<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00662948</url>
  </required_header>
  <id_info>
    <org_study_id>ZAR2007</org_study_id>
    <nct_id>NCT00662948</nct_id>
  </id_info>
  <brief_title>ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)</brief_title>
  <official_title>Open Study in Phase II to Evaluate Efficacy of Initial R-CHOP Combination in Folicular Lymphoma no Treated Previously. Consolidation w Ith One Dose of 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GELCAB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After conventional induction treatment with R-CHOP (Rituximab, cyclophosphamide, adriamycin,
      vincristine and prednisone) the patients are randomized to:

      A: Consolidation with one dose of 90Y Ibritumomab tiuxetan (Zevalin®) 0,4 mCi/Kg

      B: Maintenance with 375 mg/m2 of Rituximab every 8 weeks during 24 months
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate the benefit of consolidation treatment with 90Y Ibritumomab tiuxetan
      (Zevalin®) or maintenance with rituximab (MabThera®) in terms of progression free survival,
      after induction with chemotherapy and rituximab in folicular lymphoma patients no treated
      previously.

      The other aims are, evaluate the global survival, event free survival, time until next
      treatment, response rate after consolidation or maintenance treatment, quality of life,
      security of two branches and relation cost-efectivity
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    No inclusion
  </why_stopped>
  <start_date>December 2008</start_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Saffetty of two arms</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global survival</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate in two arms</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consolidation with one dose of 90Y Ibritumomab tiuxetan (Zevalin®) 0,4 mCi/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maintenance with 375 mg/m2 of Rituximab every 8 weeks during 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 every 8 weeks during 24 months</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibritumomab tiuxetan</intervention_name>
    <description>One dose of 90Y Ibritumomab tiuxetan, 0,4 mCi/Kg</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Folicular Lymphoma CD20-positive, grade 1, 2 or 3a, confirmed in previous 4 months.

          -  Patients no treated previously.

          -  Ann Arbor Stage II, III o IV.

          -  Symptoms or signes wich indicate necesary treatment (GELF criteria):

               -  Ganglionar or extraganglionar mass

               -  B Symptoms

               -  LDH or B2-microglobuline increased

               -  3 ganglionar territory afected (&gt; 3 cm)

               -  Esplenomegalia

               -  Compresive syndrome

               -  Pleural/peritoneal effusion

               -  Secondary medular insufiency due to infiltration

          -  Age&gt; 18 years and &lt;75 years.

          -  ECOG &lt; 2

          -  Adecuate hematological function: Hemoglobin &gt; 8,0 g/dl (5,0 mmol/L); RAN &gt;1,5 x 109/L;
             platelets &gt; 100 x 109/L

          -  No pregnant women. Women and man should use an appropiate anticonceptive method during
             the study and one year after

          -  Informed consent

        Exclusion Criteria:

          -  Transformation in high grade lymphoma

          -  FL grade 3b.

          -  Skin or gastro-intestinal primary lymphoma

          -  History of CNS diseases ( or CNS lymphoma)

          -  Previous treatment

          -  Regulary treatment with corticosteroids (permited &lt; 20 mg/day prednisone or
             equivalent).

          -  Previous cancer diseases

          -  Major surgery in 28 days before inclusion in study.

          -  Creatinine &gt; 2,0 mg/dl (197 mmol/L)

          -  Bilirubin &gt; 2,0 mg/dl (34 mmol/L), AST (SGOT) &gt; 3 x upper normal limit.

          -  HIV infection or active infection VHB o VHC &lt; 4 weeks before inclusion.

          -  Other complicated diseases

        Criteria investigador:

          -  Life expectancy &lt; 6 months.

          -  Hipersensibility to Ibritumomab tiuxetan, rituximab, other murines proteins or any
             excipients.

          -  Treatment in other experimental study in previous 30 days

          -  Any medical o psicologycal condition that can modify the capacity to give the consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Canales Miguel, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lopez-Guillermo Armando, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tomas Jose Francisco, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>MD Anderson- Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Canalejo</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital son Dureta</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia</name>
      <address>
        <city>San Sebastián</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoaspital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General</name>
      <address>
        <city>V alencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr Pesset</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://aehh.org</url>
    <description>spanish hematology association</description>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2008</study_first_submitted>
  <study_first_submitted_qc>April 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <last_update_submitted>April 23, 2017</last_update_submitted>
  <last_update_submitted_qc>April 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Folicular Lymphoma</keyword>
  <keyword>Consolidation</keyword>
  <keyword>Maintenance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

